Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04201145
Title Pembrolizumab + Defactinib In Pleural Mesothelioma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Raphael Bueno, MD
Indications

malignant pleural mesothelioma

Therapies

Pembrolizumab

Defactinib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.